RecruitingNCT07363811

Large Granular Lymphocytes in mNSCLC Treated With Nivolumab

Large Granular Lymphocytes as a Prognostic Factor in Metastatic Non-small Cell Lung Cancer Treated With Nivolumab

Sponsor

Necmettin Erbakan University

Enrollment

50 participants

Start Date

Jul 1, 2025

Study Type

OBSERVATIONAL

Conditions

Metastatic NSCLC - Non-Small Cell Lung Cancer

Summary

Large granular lymphocytes (LGLs), which constitute 10-15% of peripheral blood mononuclear cells, are large lymphocytes with a round nucleus, large cytoplasm, and azurophilic granules in the cytoplasm. Most normal LGLs in peripheral blood are natural killer (NK) cells, but some are T lymphocytes. These cells cannot be measured by a standard complete blood count (CBC) test. These cells, which can be detected by peripheral smear, are expressed numerically and as a percentage relative to other cells. The aim of this study is to determine the relationship between the percentage of LGLs at baseline and at three months and the response and clinical parameters in participants with metastatic non-small cell lung cancer treated with nivolumab in second-line therapy.

Eligibility

Min Age: 18 YearsMax Age: 90 Years

Plain Language Summary

Simplified for easier understanding

This study is observing whether the presence of certain immune cells called large granular lymphocytes (LGLs) in the blood can predict how well patients with metastatic non-small cell lung cancer (NSCLC) respond to an immunotherapy drug called nivolumab. **You may be eligible if...** - You have been diagnosed with metastatic non-small cell lung cancer (stage IV) - You are in reasonably good physical condition (ECOG score 0–2) - You have no medical reason preventing you from receiving nivolumab **You may NOT be eligible if...** - You previously received nivolumab as an adjuvant (preventive) treatment before this recurrence - You have a second active cancer currently being treated - You have another blood cancer such as leukemia or lymphoma - You have received radiation therapy or steroids in the past 3 months - You had an active bacterial or viral infection before starting nivolumab Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

Necmettin Erbakan University Faculty of Medicine, Department of Medical Oncology

Konya, Meram, Turkey (Türkiye)

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07363811

Related Trials

Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%

NCT0702006517 locations

Phase II Trial of Amivantamab Plus Monochemotherapy in Platinum Unfit NSCLC Patients With EGFR exon20 Insertion Mutations.

NCT073926581 location

Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform

NCT054785387 locations